0000000000275477

AUTHOR

Belen Ortega

showing 5 related works from this author

Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer

2021

Background Recently, microRNAs have been demonstrated to be potential non-invasive biomarkers for diagnosis, prognosis assessment or prediction of response to treatment in cancer. In this study, we evaluate the potential of miR-30b-5p as a biomarker for early diagnosis of breast cancer (BC) in tissue and plasma. Methods Expression of miR-30b-5p was determined in a series of 112 BC and 40 normal breast tissues. Circulating miR-30b-5p levels in plasma samples were determined in a discovery cohort of 38 BC patients and 40 healthy donors and in a validation cohort of 83 BC patients and 83 healthy volunteers. miR-30b-5p expression was measured by quantitative real-time PCR and receiver operating…

OncologyCancer Researchmedicine.medical_specialtydiagnosisBreast NeoplasmsBreast cancerbreast cancerPositive axillary lymph nodeInternal medicinemicroRNAmedicineBiomarkers TumorHumansStage (cooking)plasmaEarly Detection of CancerOriginal ResearchReceiver operating characteristicmicroRNAbusiness.industryCancermedicine.diseasePrognosisMicroRNAsOncologyCohortBiomarker (medicine)FemalebusinessESMO Open
researchProduct

Ten-year assessment of a cancer fast-track programme to connect primary care with oncology: reducing time from initial symptoms to diagnosis and trea…

2021

Background Cancer is the second leading cause of mortality worldwide. Integrating different levels of care by implementing screening programmes, extending diagnostic tools and applying therapeutic advances may increase survival. We implemented a cancer fast-track programme (CFP) to shorten the time between suspected cancer symptoms, diagnosis and therapy initiation. Patients and methods Descriptive data were collected from the 10 years since the CFP was implemented (2009-2019) at the Clinico-Malvarrosa Health Department in Valencia, Spain. General practitioners (GPs), an oncology coordinator and 11 specialists designed guidelines for GP patient referral to the CFP, including criteria for br…

OncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsConstitutional symptomsPrimary careMedical Oncologyprimary careBreast cancerGeneral PractitionersInternal medicinemedicineearly diagnosticHumanscancerGastrointestinal cancerStage (cooking)Lung cancerReferral and ConsultationOriginal ResearchPrimary Health Carebusiness.industryCancermedicine.diseaseOncologyFast trackbusinessESMO open
researchProduct

NOTCH signalling in ovarian cancer angiogenesis

2020

The Notch signalling pathway is involved in the new vessel formation process by regulating tip and stalk cells, which are key cells in the sprout formation. This process is essential in both normal ovary and cancer angiogenesis and is regulated by Notch-VEGF crosstalk. Furthermore, Notch has been linked in ovary with stem cell maintenance and epithelial mesenchymal transition processes. Dysregulation of the Notch pathway is frequent in ovarian cancer (OC) and it has been associated with impaired survival and advanced stages or lymph node involvement. Notch also plays a role in chemoresistance to platinum. In this context, this pathway has emerged as an attractive target for precision medici…

0301 basic medicineDemcizumabAngiogenesisNotch signaling pathway610 Medicine & healthContext (language use)General MedicineBiologymedicine.disease10174 Clinic for Gynecology03 medical and health sciencesReview Article on Ovarian Cancer: State of the Art and Perspectives of Clinical Research030104 developmental biology0302 clinical medicine030220 oncology & carcinogenesismedicineCancer researchEpithelial–mesenchymal transitionStem cellOvarian cancerGamma secretaseAnnals of Translational Medicine
researchProduct

Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer

2020

MicroRNAs have emerged as new diagnostic and therapeutic biomarkers for breast cancer. Herein, we analysed miR-99a-5p expression levels in primary tumours and plasma of breast cancer patients to evaluate its usefulness as a minimally invasive diagnostic biomarker. MiR-99a-5p expression levels were determined by quantitative real-time PCR in three independent cohorts of patients: (I) Discovery cohort: breast cancer tissues (n = 103) and healthy breast tissues (n = 26)

Oncologymedicine.medical_specialtydiagnosisDown-RegulationBreast NeoplasmsReal-Time Polymerase Chain ReactionArticleCatalysislcsh:ChemistryInorganic Chemistrybreast cancerBreast cancerInternal medicinemicroRNABiomarkers TumorHumansMedicineDiagnostic biomarkerCirculating MicroRNAPhysical and Theoretical Chemistryskin and connective tissue diseaseslcsh:QH301-705.5Molecular BiologyEarly Detection of CancerplasmaSpectroscopyRetrospective StudiesEarly breast cancerPlasma samplesbusiness.industryOrganic ChemistryGeneral MedicineMiddle Agedmedicine.diseaseComputer Science ApplicationsGene Expression Regulation NeoplasticMicroRNAsROC Curvelcsh:Biology (General)lcsh:QD1-999Potential biomarkersCohortbiomarkerBiomarker (medicine)FemalebusinessInternational Journal of Molecular Sciences
researchProduct

Clinical application of mutational analysis in breast cancer patients: The relevance of PIK3CA analysis for precision medicine

2019

Abstract Background The identification of biomarkers to drive treatment is one of the most important objectives of precision medicine. During last years, the role of PIK3CA mutations have been related to clinical benefit deriving from treatment with PI3K, and mTOR inhibitors. In breast cancer (BC), PIK3CA mutations are widely present and the use, in clinical trials, of selective inhibitors improved clinical outcomes. The aim of this study is to assess the value of a monocentric genomic screening program to select patients for trials with experimental targeted agents. Methods We examined PIK3CA mutation in a cohort of 312 metastatic BC patients diagnosed at Hospital Clinico Valencia-INCLIVA …

0301 basic medicinemedicine.medical_specialtybusiness.industryHematologymedicine.diseaseDiscovery and development of mTOR inhibitorsPrecision medicineGenomic screeningClinical trialMutational analysis03 medical and health sciences030104 developmental biology0302 clinical medicineBreast cancerOncology030220 oncology & carcinogenesisInternal medicineCohortmedicinebusinessTriple negativeAnnals of Oncology
researchProduct